AstraZeneca’s acknowledgment of the rare side effect of blood clotting linked to its Covid-19 vaccine has sparked concerns among Covishield recipients in India. However, experts emphasize the importance of understanding the post-vaccination risks and conducting a thorough risk-benefit analysis.
The company’s admission in court regarding the side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS) echoes earlier findings in scientific literature. While the Government committee on Adverse Events Following Immunisation (AEFI) in India has confirmed cases of TTS and associated deaths, legal complexities may hinder Indian patients from participating in British lawsuits against AstraZeneca.
Read more : Firm warns Delhi high court of India exit over encryption
Despite these developments, experts advise against panic. TTS, though reported in Europe early in the pandemic, has been rare in India, particularly among South Asians. Moreover, the risk is highest in the initial weeks following the first dose, with most Indians having received multiple doses by now.
Reassuringly, the benefits of vaccination in saving lives during the pandemic have consistently outweighed the risks, according to health officials and experts. Notably, Covishield’s package insert has always included a warning about this rare condition.
Data from a Lancet Global Health study highlight geographic variations in TTS reporting, with Nordic countries reporting higher rates compared to Asian countries.
Read more : Why Covishield vaccine takers in India shouldn’t panic
As for current vaccination recommendations, experts suggest that for most individuals, especially those with high antibody levels due to prior infection, there may not be an immediate need for vaccination. However, certain populations, such as the immunocompromised, may still benefit from newer vaccines offering protection against emerging variants like Omicron. Additionally, considerations may vary for specific demographics, such as younger women at lower risk of severe disease.
In summary, while acknowledging the rare side effect associated with the AstraZeneca vaccine, the message remains one of cautious evaluation, reassurance regarding the rarity of the condition, and consideration of individual risk factors and vaccination needs.
